rapeutic approaches that add to
the breadth and depth of our product pipeline," said Dr Jurgen
Engel, Executive Vice President, Global R&D and Chief Operating
Officer at AEterna Zentaris. "The potential for cancer treatment
with agents inhibiting the PI3K pathway has become a focus in
recent drug discovery and development research. We believe that by
developing novel selective PI3K inhibiting small molecular
compounds, we are positioning ourselves as one of the leaders in
this promising therapeutic approach."
Cellular substrate phosphorylation studies targeting the
inhibition of PI3K and functional cellular assays of tumor cell
proliferation have been performed. In addition, physicochemical and
initial ADMET data were collected. Several derivatives are
currently undergoing first pharmacokinetic in vivo studies.
About AEterna Zentaris Inc.
AEterna Zentaris Inc. is a global, pure play biopharmaceutical
company focused on endocrine therapy and oncology with proven
expertise in drug discovery, development and commercialization.
News releases and additional information are available at
www.aeternazentaris.com
Forward-Looking Statements
This press release contains forward-looking statements made
pursuant to the safe harbor provisions of the U.S. Securities
Litigation Reform Act of 1995. Statements that are not historical
facts, including statements preceded by, followed by, or that
include the words "believes", "anticipates", "intends", "plans",
"expects", "estimates", "will," "may", "should", "approximately",
and the negative or other variations of those terms or comparable
terminology, are forward-looking statements. Such statements
reflect management's current views, intentions, strategies and
plans and are based on certain assumptions.
Forward-looking statements involve known and unknown risks and
uncertainties, which could cause the Company's actual res
'"/>
Page: 1 2 3 Related medicine technology :1.
AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results
for Anti-Cancer Compound Perifosine at ASCO Meeting2.
AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2
Data for Ozarelix, in BPH at Annual AUA Meeting3.
AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist
JMR-132 at the AACR Annual Meeting in Los Angeles4.
AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors
and In Vivo Results for a GHRH Antagonist at the AACR Annual
Meeting in Los Angeles5.
AEterna Zentaris Reports Positive Results with Cetrorelix in BPH
for Japanese Phase 2a Trial6.
terna Zentaris Discloses First In Vitro Data for its PI3K
Inhibitors at the AACR Annual Meeting in Los Angeles7.
Data Available From Erbitux Phase III Study in First-Line Treatment
of Advanced Lung Cancer8.
Pixantrone Combination Therapy for First-line Treatment of
Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe
Toxicities Including Heart Damage When Compared to
Doxorubicin-based Therapy9.
Genzyme Announces Data from First Phase 3 Study of Tolevamer in
Patients with C. difficile Associated Diarrhea10.
Ablynx Announces Interim Results of First Nanobody Phase I Study of
ALX-0081 (ANTI-VWF)11.
Advanced Life Sciences Announces Supplemental Efficacy Data from
First Pivotal Phase 3 Pneumonia Clinical Trial